Claims for Patent: 8,129,385
✉ Email this page to a colleague
Summary for Patent: 8,129,385
Title: | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Abstract: | The present invention is directed to a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-di- ones useful as anti-HIV agents. The compounds have the formula: ##STR00001## Z.dbd.O; R.sup.20, R.sup.21, R.sup.22, R.sup.23, R.sup.24 and R.sup.25 independently are hydrogen, C.sub.1-C.sub.8 alkyl, (C.sub.6-C.sub.14)aryl-(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.14 aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; R.sup.X is hydrogen; R.sup.14 is hydrogen or optionally substituted lower alkyl; R.sup.3 is hydrogen; R.sup.1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof. |
Inventor(s): | Johns; Brian Alvin (Research Triangle Park, NC), Kawasuji; Takashi (Osaka, JP), Taishi; Teruhiko (Osaka, JP), Taoda; Yoshiyuki (Osaka, JP) |
Assignee: | Shionogi & Co., Ltd. (Osaka, JP) GlaxoSmithKline LLC (Philadelphia, PA) |
Application Number: | 11/919,386 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,129,385 |
Patent Claims: |
1. A compound of the formula: ##STR00212## wherein, ring A is ##STR00213## R.sup.20, R.sup.21, R.sup.22, R.sup.23, R.sup.24 and R.sup.25 are independently hydrogen,
C.sub.1-C.sub.8alkyl, C.sub.6-C.sub.14arylC.sub.1-C.sub.8alkyl, C.sub.6-C.sub.14aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; R.sup.X is hydrogen; R.sup.14 is hydrogen
or lower alkyl which is optionally substituted with I to 4 substituents selected from the group consisting of hydroxy, carboxy, halogen, halo lower alkyl, halo lower alkoxy, lower alkyl, lower alkenyl, lower alkynyl. cycloalkyl, cycloalkenyl, lower
alkoxy, lower alkenyloxy, lower alkoxycarbonyl, nitro, nitroso, amino, alkylamino, acylamino, aralkylamino, aryl, aralkyl. cyano, isocyano, isocyanate, thiocyanate, isothiocyanate, mercapto, alkylthio, alkylsulfonyl, alkylsulfonylamino, carbamoyl,
alkylcarbamoyl, sulfamoyl, acyl, formyloxy. haloformyl, oral, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, sulfoamino, hydrazino, azido, ureido, guanidino, phthalimide, oxo, phosphoric acid, lower alkyl which is substituted
with phosphoric acid and may be intervened with a heteroatom, aryl substituted with phosphoric acid, aralkyl substituted with phosphoric acid and hydroxy lower alkyl; R.sup.3 is hydrogen; R.sup.1 is hydrogen or lower alkyl; R is halogen; and m is 1,
2 or 3; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sup.X is hydrogen; R.sup.14 is hydrogen; R.sup.3 is hydrogen; m is 1, 2 or 3 and R is halogen. 3. A compound according to claim 1 wherein the pharmaceutically acceptable salt is a sodium salt. 4. A compound of formula (1-7): ##STR00214## wherein: R.sup.a is --CH.sub.3, --CH(CH.sub.3).sub.2, or --CH.sub.2CH.sub.2OCH.sub.3, and (R)m and the phenyl ring to which it is attached is 4-fluorophenyl, 2,4-difluorophenyl or 3-chloro-2-fluorophenyl; or a pharmaceutically acceptable salt thereof. 5. A compound selected from the group consisting of: (3S,9aS)-5-Hydroxy-3-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (3R,9aR)-5-Hydroxy-3-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (4S,9aR)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2R,9aR)-5-Hydroxy-2-methoxymethyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-- 1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aS)-5-Hydroxy-2-methoxymethyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-- 1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aR)-2-Ethyl-5-hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a- ,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2R,9aS)-2-Ethyl-5-hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a- ,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aS)-5-Hydroxy-6,10-dioxo-2-phenyl-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aS)-5-Hydroxy-2-isopropyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-ox- a-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2R,9aR)-5-Hydroxy-2-isopropyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-ox- a-4a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (3S,9aS)-5-Hydroxy-3-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; (3R,9aR)-5-Hydroxy-3-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; (2R,9aS)-5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aR)-5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; (2S,9aR)-5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; (2R,9aS)-5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; 5-Hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diazaanthrace- ne-7-carboxylic acid 4-fluorobenzylamide; 5-Hydroxy-3,3-dimethyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-- diaza-anthracene-7-carboxylic acid 4-fluoro-benzylamide; 5-Hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diza- zaanthracene-7-carboxylic acid 4-fluorobenzylamide; 5-Hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthrac- ene-7-carboxylic acid 2,4-difluoro-benzylamide; 5-Hydroxy-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthrac- ene-7-carboxylic acid 3-chloro-2-fluoro-benzylamide; enantiomers thereof; diastereomers thereof; mixtures of enantiomers thereof; mixtures of diastereomers thereof; mixtures of enantiomers and diastereomers thereof; and pharmaceutically acceptable salts thereof. 6. A compound selected from the group consisting of (4R,9aS)-5-Hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide; an enantiomer thereof; diastereomer thereof; mixtures of enantiomers thereof; mixtures of diastereomers thereof; mixtures of enantiomers and diastereomers thereof; or a pharmaceutically acceptable salt thereof. 7. A compound which is (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide or a pharmaceutically acceptable salt thereof. 8. A compound which is (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic ac id 2,4-difluoro-benzylamide sodium salt. 9. A compound which is (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide. 10. A pharmaceutical composition comprising (4R,9aS)-5-hydroxy-4-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4- a,8a-diaza-anthracene-7-carboxylic acid 2,4-difluoro-benzylamide or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent. 11. A pharmaceutical composition comprising a compound according to any one of claims 1, 5, 6, 7, 8, 9 or 4, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent. |